CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Optical Coherence Tomography (OCT)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D011655 Pulmonary Embolism NIH 0.32
D004617 Embolism NIH 0.30

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002204 Pulmonary embolism HPO 0.32

There is one clinical trial.

Clinical Trials

1 Optical Coherence Tomography for Microvascular Lung Vessels Obstructive Thromboinflammatory Syndrome Assessment in Patients With COVID-19: an Exploratory Study

To evaluate by intravascular OCT study the presence of microvascular pulmonary thrombosis in patients with COVID-19, high D-dimer levels and contrast CT scan negative for pulmonary thrombosis. We'll also evaluate the extension of microvascular pulmonary thrombosis in patients with contrast CT scan positive for pulmonary embolism in areas where contrast CT scan was negative.

NCT04410549 Covid19 Pulmonary Embolism Diagnostic Test: Optical Coherence Tomography (OCT)
MeSH:Pulmonary Embolism Embolism
HPO:Pulmonary embolism

Primary Outcomes

Description: Study primary endpoints will be evaluation of OCT procedure overall safety in COVID-19 pneumonia patients and assessment of the presence of microvascular pulmonary thrombosis in COVID-19 patients, both in "ground glass" and "healthy" ventilated areas.

Measure: optical coherence tomography pulmonary microthrombosis assessment in COVID-19 pneumonia patients

Time: through study completion, an average of 1 month

Secondary Outcomes

Description: Pulmonary artery vessel anatomy characterization in COVID-19 pneumonia patients through OCT diagnostic technique Correlations with single trans-thoracic echocardiography (TTE) pulmonary hypertension (PH, estimated systolic pulmonary artery pressure > 35 mmHg) and right ventricular disfunction (RVD: tricuspid annular plane systolic excursion < 17 mm or Doppler tissue imaging S wave < 9.5 cm/sec). Dynamic correlations with standard inflammatory, coagulation and tissue damage biomarkers: CRP, ferritin, D-dimer, NT-proBNPO, troponins, LDH)

Measure: Pulmonary artery vessel anatomy characterization

Time: through study completion, an average of 1 month

Description: Correlations with single trans-thoracic echocardiography (TTE) pulmonary hypertension (PH, estimated systolic pulmonary artery pressure > 35 mmHg) and right ventricular disfunction (RVD: tricuspid annular plane systolic excursion < 17 mm or Doppler tissue imaging S wave < 9.5 cm/sec)

Measure: Correlation between TTE pulmonary hypertension and right ventricular disfunction

Time: through study completion, an average of 1 month

Description: Pneumonia COVID-19 dynamic correlation with inflammation and coagulation markers

Measure: Correlations with standard inflammatory, coagulation and tissue damage

Time: through study completion, an average of 1 month

Related HPO nodes (Using clinical trials)

HP:0002204: Pulmonary embolism
Genes 43
HABP2 IL23R IL12A SERPINC1 HLA-B CBS ERAP1 KCNJ5 PROS1 SMAD4 GNAQ CCR1 PROC ACVRL1 F2 PROC PTEN SERPINC1 MTHFR KLRC4 ENG CD55 GDF2 AKT1 TET2 PLP1 MEFV C4A IL12A-AS1 MPL AGGF1 UBAC2 TLR4 PROS1 PROC IL10 F13A1 PIGA FAS GNAQ JAK2 PROS1 STAT4
Protein Mutations 2
G20210A G21210A
SNP 0